Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension

P. K. Zachariah, C. Shub, S. G. Sheps, A. Schirger, M. K. Wolf, C. A. Carlson

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil. The mean P-R interval in 22 patients taking placebo and immediate-release verapamil was 0.18 second. The borderline first-degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P-R interval longer than 0.20 second and of those with a P-R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained-release verapamil had a maximal mean P-R interval of 0.19 ± 0.01 second during 24-hour ambulatory electrocardiographic monitoring. P-R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P-R prolongation occurred with oral verapamil therapy, but no patient, reggardless of baseline P-R interval, developed high-grade atrioventricular block.

Original languageEnglish (US)
Pages (from-to)843-847
Number of pages5
JournalJournal of Clinical Pharmacology
Volume28
Issue number9
StatePublished - 1988

Fingerprint

Verapamil
Atrioventricular Block
Ambulatory Electrocardiography
Essential Hypertension
Placebos
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zachariah, P. K., Shub, C., Sheps, S. G., Schirger, A., Wolf, M. K., & Carlson, C. A. (1988). Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension. Journal of Clinical Pharmacology, 28(9), 843-847.

Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension. / Zachariah, P. K.; Shub, C.; Sheps, S. G.; Schirger, A.; Wolf, M. K.; Carlson, C. A.

In: Journal of Clinical Pharmacology, Vol. 28, No. 9, 1988, p. 843-847.

Research output: Contribution to journalArticle

Zachariah, PK, Shub, C, Sheps, SG, Schirger, A, Wolf, MK & Carlson, CA 1988, 'Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension', Journal of Clinical Pharmacology, vol. 28, no. 9, pp. 843-847.
Zachariah PK, Shub C, Sheps SG, Schirger A, Wolf MK, Carlson CA. Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension. Journal of Clinical Pharmacology. 1988;28(9):843-847.
Zachariah, P. K. ; Shub, C. ; Sheps, S. G. ; Schirger, A. ; Wolf, M. K. ; Carlson, C. A. / Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension. In: Journal of Clinical Pharmacology. 1988 ; Vol. 28, No. 9. pp. 843-847.
@article{727e1126cb354ee8bff690ead33aabd6,
title = "Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension",
abstract = "Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil. The mean P-R interval in 22 patients taking placebo and immediate-release verapamil was 0.18 second. The borderline first-degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P-R interval longer than 0.20 second and of those with a P-R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained-release verapamil had a maximal mean P-R interval of 0.19 ± 0.01 second during 24-hour ambulatory electrocardiographic monitoring. P-R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P-R prolongation occurred with oral verapamil therapy, but no patient, reggardless of baseline P-R interval, developed high-grade atrioventricular block.",
author = "Zachariah, {P. K.} and C. Shub and Sheps, {S. G.} and A. Schirger and Wolf, {M. K.} and Carlson, {C. A.}",
year = "1988",
language = "English (US)",
volume = "28",
pages = "843--847",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Correlation between verapamil plasma concentration and P-R prolongation in essential hypertension

AU - Zachariah, P. K.

AU - Shub, C.

AU - Sheps, S. G.

AU - Schirger, A.

AU - Wolf, M. K.

AU - Carlson, C. A.

PY - 1988

Y1 - 1988

N2 - Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil. The mean P-R interval in 22 patients taking placebo and immediate-release verapamil was 0.18 second. The borderline first-degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P-R interval longer than 0.20 second and of those with a P-R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained-release verapamil had a maximal mean P-R interval of 0.19 ± 0.01 second during 24-hour ambulatory electrocardiographic monitoring. P-R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P-R prolongation occurred with oral verapamil therapy, but no patient, reggardless of baseline P-R interval, developed high-grade atrioventricular block.

AB - Plasma verapamil concentration was correlated with serial electrocardiographic P-R intervals in patients with essential hypertension receiving immediate-release (80 to 120 mg three times a day) or sustained-release (240 mg daily) verapamil. The mean P-R interval in 22 patients taking placebo and immediate-release verapamil was 0.18 second. The borderline first-degree atrioventricular block of three patients did not change during treatment. Plasma verapamil concentrations of patients with a P-R interval longer than 0.20 second and of those with a P-R interval of 0.20 second or less were 169 ± 73 ng/mL and 63 ± 8 ng/mL, respectively. Six patients taking sustained-release verapamil had a maximal mean P-R interval of 0.19 ± 0.01 second during 24-hour ambulatory electrocardiographic monitoring. P-R intervals were 0.22 second or more in two patients, but they returned to normal by hour 7 for one and by hour 20 for the other patient. In summary, transient P-R prolongation occurred with oral verapamil therapy, but no patient, reggardless of baseline P-R interval, developed high-grade atrioventricular block.

UR - http://www.scopus.com/inward/record.url?scp=0024215025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024215025&partnerID=8YFLogxK

M3 - Article

C2 - 3230151

AN - SCOPUS:0024215025

VL - 28

SP - 843

EP - 847

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 9

ER -